Autism is a biologically-heterogeneous disease. Distinct subgroups of autistic patients may be marked by intermediate phenotypes, such as elevated serotonin (5-HT) blood levels, potentially associated with different underlying disease mechanisms. This could lead to inconsistent genetic association results, such as those of prior studies on serotonin transporter (5-HTT) gene promoter variants and autistic disorder. Contributions of 5-HTT gene promoter alleles to 5-HT blood levels were thus investigated in 134 autistic patients and 291 first-degree relatives. Mean 5-HT blood levels are 11% higher in autistic patients carrying the L/L genotype, compared to patients with the S/S or S/L genotype; this trend is not observed in first-degree relatives. The probability of inheriting L or S alleles is significantly enhanced in patients with 5-HT blood levels above or below the mean, respectively (P Ͻ 0.05), but quantitative TDT analyses yield a non-significant trend (P = 0.10), as this polymorphism explains only 2.5% of the variance in 5-HT blood levels of autistic patients. In conclusion, 5-HTT gene promoter variants seemingly exert a small effect on 5-HT blood levels in autistic children, which largely does not account for hyperserotoninemia. Nonetheless, the inconsistent outcome of prior association studies could partly stem from a selection bias of hyper-or hypo-serotoninemic probands.
Family-based association studies between serotonin transporter (5-HTT) gene promoter alleles and autistic disorder have thus far produced contrasting evidence, supporting either linkage/association with the short 'S' allele, 1 or with the long 'L' allele, [2] [3] [4] or no linkage/association at all. 5, 6 Our prior study described a lack of association between 5-HTT gene promoter alleles and autistic disorder in 46 Italian and 44 Caucasian-American complete trios. 6 We have subsequently collected 65 additional complete Italian trios with autistic probands, surprisingly displaying a significant preferential transmission of the L allele to affected offspring, with 78 transmissions and 63 nontransmissions of the L allele in autistics (HHRR 2 = 3.90, 1 df, 2-tail P Ͻ 0.05) vs 38 transmissions and 40 non-transmissions in unaffected sibs from the same families (autistics vs unaffected sibs: HHRR 2 = 5.82, 1 df, 2-tail P Ͻ 0.05). Both maternal and paternal transmission display the same trend, but only the latter reaches statistical significance (paternal transmission: HHRR 2 = 4.74, 1 df, 2-tail P Ͻ 0.05). Our combined sample of 155 complete trios, to our knowledge the largest assessed to date, still yields no significant evidence of association (Table 1) . Nonetheless, recurrent inconsistencies among association studies of complex disorders spur interest into potential underlying pathogenetic heterogeneity. Biological markers could conceivably identify subgroups of autistic patients with common underlying disease mechanisms. Serotonin (5-HT) blood level, consistently elevated in at least 25% of autistic patients, indeed represents one of the best-characterized intermediate phenotypes in autism, and possibly a marker for familial forms of the disease. 7, 8 Hyperserotoninemia indeed appears to be genetically determined. 8 It entirely stems from elevated 5-HT amounts in platelets, with no change in free 5-HT plasma level, and seemingly derives from increased density of functionallyactive 5-HTT molecules on platelet membranes from autistic patients, with no difference in affinity for 5-HT. [9] [10] [11] The polymorphic repetitive element assessed in this study profoundly affects 5-HTT gene expression, with the dominant S allele reducing gene expression by approximately 50% in S/S and S/L genotypes, compared to the L/L genotype. 12 A similar effect on 5-HTT V max has also been documented in human platelets. 13, 14 The L/L genotype could thus contribute to the enhanced 5-HT uptake leading to elevated 5-HT blood levels in a consistent subgroup of autistic patients. In this case, a recruitment biased by chance toward probands with 5-HT blood levels either in the high or in the low range could be predicted to yield opposite linkage/association outcomes at this locus.
We have assessed the contribution of this polymorphic repetitive element to 5-HT blood levels in 134 autistic children and 291 first-degree relatives not taking selective serotonin reuptake inhibitors (SSRIs) at the time of blood drawing. Mean 5-HT blood levels by family status and 5-HTT genotype are displayed in Figure 1 . Family status has a major influence on 5-HT blood levels: autistic children and unaffected sibs display 5-HT blood levels significantly higher, by 38.5% and 20.7% respectively, compared to their mothers and fathers combined (two-way ANOVA: F = 9.495; df 3,422; P Ͻ 0.001), and do not significantly differ from one another. The overall influence of 5-HTT genotype is not significant (two-way ANOVA: F = 0.068; df 2,422; P = 0.93, NS). Indications of status × genotype interactions are found both in 87 complete and 12 incomplete Italian trios (two-way ANOVA: F = 2.688; df 6,298; P Ͻ 0.05), and in 35 complete CaucasianAmerican trios (two-way ANOVA: F = 2.149; df 6,123; P Ͻ 0.1). In particular, 41 autistic children carrying the L/L genotype show an 11% higher mean 5-HT blood level compared to 91 patients carrying either the S/S or the S/L genotypes ( Figure 1 ). This trend is present neither in parents, nor in unaffected siblings, but only among affected children ( Figure 1 ).
The distributions of 5-HT blood levels by family status are shown in Figure 2 . First-degree relatives display approximately unimodal distributions, whereas autistic patients display a broader, possibly even bimodal distribution as previously suggested by others, 15 peaking at approximately 140 and 270 ng ml
. Allelic transmission patterns diverge significantly between patients at or above vs below the mean 5-HT level of 226 ng ml −1 ( Figure 2 ). Autistic patients with elevated 5-HT blood levels display preferential transmission of the L allele, while patients below 226 ng ml −1 of 5-HT show more modest trends in the opposite direction ('high' vs 'low' 5-HT: HHRR 2 = 4.01, 1 df, 2-tail P Ͻ 0.05). No obvious difference in transmission patterns is seen in unaffected siblings, employing the mean value of 197 ng ml −1 as cut-off ( Figure 2 ). Using a quantitative TDT method, 16 the familyspecific component of variance was estimated to be 0.05 and the residual component was 0.26; the relative contribution of family-specific factors to the variability in 5-HT blood levels is thus minor. Unadjusted analyses, more powerful but not of guaranteed validity in the presence of population admixture or stratification, yield a non-significant trend (P = 0.10) toward higher 5-HT blood levels in autistic offspring carrying the L/L genotype ( Table 2) . Adjusted analyses, less powerful but able to control for admixture or stratification, produce larger non-significant P-values ( Table 2 ). The insufficient power of these analyses likely stems from large interindividual variability in 5-HT blood levels (see SEM values in Figure 1 and Table 2 ), and from the relatively small effect size of the association between the L/L genotype and elevated 5-HT blood levels ( Figure 1 ). Hierarchical multiple regression shows that 5-HTT genotype only explains 2.5% of variance in 5-HT blood levels, with an additional 1.6% explained by urinary peptide excretion rates. This variable was included in the model on the basis of prior stepwise multiple regressions (see Materials and Methods), and it is the only other biochemical or phenotypic variable moderately correlated with 5-HT blood levels (r = 0.16) in our sample. Urinary peptide excretion rates are significantly more elevated in affected and unaffected children, compared to their parents (AM Persico, F Keller, KL Reichelt, manuscript in preparation), and non-significantly higher in patients carrying at least one copy of the L allele (two-way ANOVA: Status, F = 8.296; df 3,296; P Ͻ 0.001; 5-HTT genotype, F = 0.233; df 2,296; P = 0.792, NS; status × 5-HTT genotype interaction F = 1.463; df 6,296; P = 0.191, NS). Mean (±SEM) urinary excretion rates in autistic patients carrying the S/S (n = 24), S/L (n = 50), and L/L (n = 30) genotypes are 337 ± 27.4, 499.5 ± 58.6, and 426.1 ± 42.1 m 2 , respectively. Preliminary assessments of 5-HT blood levels and 5-HTT genotypes were also performed in nine autistic children, nine mothers, six fathers, and one unaffected sibling taking SSRI drug treatment and excluded from prior analyses. As expected, 5-HT blood levels in all these subjects are dramatically reduced, ranging from undetectable to a maximum of 97 ng ml −1 . Mean 5-HT blood levels are 52 ng ml −1 in two autistics with the L/L genotype vs 18 and 22 ng ml −1 in three patients carrying the S/S and four with the S/L genotype, respectively. Again, no trend is present in 16 SSRI-treated first-degree relatives (data not shown). Should future research specifically targeted to SSRI-treated individuals confirm these very preliminary findings, work will have to focus on the mechanisms through which SSRIs may strikingly unveil 5-HTT genotype effects in vivo, closely resembling those observed in vitro. 12 The current results replicate and extend our prior findings, 6 suggesting that 5-HTT gene promoter variants may exert a detectable, albeit small effect on 5-HT blood levels in autistic individuals only. Enhanced 5-HT blood levels in patients, but not in first-degree relatives with the L/L genotype, point toward interactive contributions to serotoninemia both by 5-HTT gene variants and by other autism-related loci. Confounding variables, such as race and pubertal status, 17 are unlikely to explain 5-HTT genotype influences on 5-HT blood levels. All individuals recruited in this study are of Caucasian origin, 90.8% of autistic patients were 10 years old or younger at the time of blood drawing, and patients differing by 5-HTT genotype display superimposable age distributions (data not shown). Autistics and unaffected siblings do, however, differ significantly in age, with only 68.3% of unaffected siblings being 10 years old or younger when recruited in this study. Also, larger samples of unaffected siblings will have to be assessed to conclusively exclude an effect of 5-HTT gene variants in all prepubertal children, either affected or unaffected, which could be overrun by the blunting effect of sex hormones on 5-HT transport following puberty. 17, 18 Our sample includes a seizable subgroup of patients displaying 5-HT blood levels well below mean values even of unaffected siblings (Figure 2 ). Autistic patients with reduced 5-HT blood levels could potentially share common neurobiological underpinnings, as originally proposed for 'hyperserotoninemic' patients. 7 Converging evidence, for example, points toward a dysregulation of the immune system in autistic children, as discussed elsewhere. 19 Patients with reduced 5-HT blood levels could be characterized by more intense autoimmune activation, shunting tryptophan toward the kynurenine pathway and reducing substrate availability for 5-HT synthesis and subsequent uptake by platelets. This process could occur systemically, but also within the central nervous system of autistic individuals, as recently suggested by positron emission tomography (PET) studies. 20 Interesingly, plasma concentrations of tryptophan are significantly decreased in autistics, compared to unaffected controls. 7, 21 More research into the relationship between tryptophan and free 5-HT plasma levels, platelet 5-HT content, and specific markers of immune function will be required to address this issue.
The molecular bases of 5-HTT gene variant contributions to 5-HT blood levels are especially intriguing. Our results indicate that the 5-HTT gene promoter variants assessed in this study largely do not explain the variance in 5-HT blood levels of autistic patients. Other polymorphisms within regulatory or coding sequences at the 5-HTT locus could be more directly linked to this phenotype. At least two additional mechanisms may also intervene. First, platelet 5-HT transport is apparently stimulated by oligopeptides isolated from the urines of normal individuals and of some autistic children. 22, 23 Qualitatively and/or quantitatively altered production of these oligopeptides could potentially exert a major influence on platelet 5-HT accumulation. The modest yet positive correlation between urinary peptide excretion rates and 5-HT blood levels found in our sample, and the inverse correlation between 5-HT blood levels and pain reactivity, possibly due to increased activity of endogenous opioid peptides, 24 point in this direction. Second, concomitant alterations of post-translational processing of 5-HTT protein may be required for full phenotypic expression. For example, phosphorylation is known to profoundly affect 5-HTT function. 25, 26 The 5-HTT is assembled with protein phosphatase 2A (PP2A), and phosphorylation of the 5-HTT by protein-kinase C (PKC) causes its detachment from PP2A, followed by 5-HTT internalization. 27 Decreased phosphorylation due to altered interactions between 5-HTT, PP2A and PKC, could directly enhance the number of active 5-HTT molecules at the cell surface. Biochemical studies of 5-HTT function in platelets of autistic and control individuals may represent a more direct strategy aimed at identifying other proteins involved in altered protein-protein interactions with the 5-HTT, than use of classical genetic linkage approaches to identify the genes responsible for their synthesis.
Materials and methods

Clinical sample and experimental procedures
Genotyping of 5-HTT gene promoter variants was performed on 163 trios from 151 singleton and five multiplex families with primary autistic probands, including the 90 complete and eight incomplete trios described in our prior report, 6 as well as 65 additional complete trios of Italian descent. Inclusion criteria, diagnostic screening methods, and clinical characterization measures have been previously reported. 6, 19, 28 All parents provided written informed consent for themselves and for their children. The informed consent form was approved by the IRB of UCBM.
Serotonin blood levels were measured in plateletrich plasma (PRP) by HPLC, as previously described. 24 Urinary peptide excretion analysis was performed by HPLC on the first morning urine samples of all family members, as described. 19, 28 The total area of peaks under the 215 nm absorption curve (AUC) in the peptide region following the hippuric acid peak was calculated and expressed in m 2 .
Statistical analyses
Linkage/association analyses were performed applying the transmission/disequilibrium test (TDT) 29 and the haplotype-based haplotype relative risk (HHRR), 30 which may be slightly more powerful 29 and is thus being reported. In the absence of specific functional studies, the rare 18-repeat 'very-long' allele was assimilated to a 'long' allele in linkage/association analyses.
The relationship between the independent variables 'family status' and '5-HTT genotype', and either '5-HT blood level' or 'urinary peptide excretion rates' as the dependent variable, was assessed on both complete and incomplete trios by two-way analysis of variance (ANOVA) followed by Student-Newman-Keuls posthoc tests. Quantitative TDT analyses were performed on complete trios only, from 117 families including 120 autistic children and 41 unaffected sibs, as described, 16 assuming a dominant effect for the S allele on the basis of in vitro evidence. 12 Both ANOVA and quantitative TDT analyses were performed following square root transformation of the dependent variable, to achieve approximately normal distributions. Parental genotype data were used to adjust for potential bias due to population admixture or stratification. 16 Linear random effects models with family-specific random intercept terms were used to account for possible within-family correlation in the dependent variable. To adjust for population admixture, regressors in the random effects model were augmented by their conditional expectation given the parental genotypes. 16 Hierarchical multiple regressions were performed using square root-transformed 5-HT blood levels as the dependent variable, and 5-HTT genotype (L/L vs S/S-S/L) and square root-transformed peptiduria values as Molecular Psychiatry independent variables forced into the model in this order. Independent variables were chosen based on preliminary stepwise multiple regressions showing no correlation trends with other independent variables, such as age, cranial circumference, weight and height.
